Tagrisso (osimertinib) costs roughly $18,000 per monthly cycle in the United States, putting its annual price tag well above $200,000 for many patients. That price reflects a combination of patent-protected market exclusivity, AstraZeneca’s pricing power as the sole manufacturer of a best-in-class targeted therapy, and the broader economics of oncology drug pricing in the U.S.
What Tagrisso Treats and Why It Dominates
Tagrisso targets a specific mutation in non-small cell lung cancer called EGFR. About 10 to 15 percent of lung cancer patients in the U.S. carry this mutation, and for them, Tagrisso has become the standard first-line treatment. It also crosses the blood-brain barrier more effectively than older drugs in the same class, which matters because EGFR-mutant lung cancers frequently spread to the brain.
The FDA granted Tagrisso both breakthrough therapy designation and priority review, fast-tracking its path to market. Those designations signal that regulators considered it a meaningful advance over existing options. AstraZeneca has since expanded its approved uses to include earlier-stage disease and post-surgery treatment, broadening the pool of patients who take the drug and extending the typical duration of treatment.
Patent Protection Until 2035
One of the biggest reasons Tagrisso stays expensive is straightforward: no generic version exists, and none can legally enter the U.S. market for years. FDA records show the last qualifying patent on osimertinib doesn’t expire until January 2, 2035. That gives AstraZeneca over a decade of remaining exclusivity from today, during which no competitor can manufacture a generic copy.
Without generic competition, there is no downward pressure on the price. AstraZeneca sets the price, insurers negotiate modest rebates behind closed doors, and patients face the list price or something close to it. This is the same dynamic that keeps many branded cancer drugs expensive, but the 2035 expiration date means Tagrisso’s high price is locked in for longer than many patients realize.
The Cost-Effectiveness Problem
Health economists evaluate whether a drug’s price is justified by calculating how much it costs per “quality-adjusted life year,” or QALY, which essentially measures how much additional healthy time a drug buys. In the U.S., the commonly accepted threshold is $150,000 per QALY. A drug priced below that benchmark is generally considered cost-effective.
Tagrisso doesn’t meet that bar. An international cost-effectiveness analysis published in Frontiers in Public Health found that in the U.S., Tagrisso’s total treatment cost came to roughly $898,000 per patient, with a cost-effectiveness ratio of $322,308 per QALY. That’s more than double the accepted threshold. In practical terms, this means the price is significantly higher than what economists would consider a fair reflection of the drug’s clinical benefit.
A real-world survival analysis comparing Tagrisso to older, less expensive EGFR drugs (like erlotinib and gefitinib) adds context. With a median follow-up of over six years, overall survival was essentially identical: 16.9 months for Tagrisso versus 16.6 months for earlier-generation drugs. Tagrisso does delay disease progression longer than older options, but the fact that overall survival looks comparable in real-world data raises legitimate questions about whether the price premium is proportional to the benefit.
Oncology Pricing and Market Dynamics
Tagrisso isn’t uniquely expensive among cancer drugs. It exists in a market where new oncology treatments routinely launch at six-figure annual prices. Several forces keep those prices elevated. The U.S. government does not directly negotiate drug prices for most commercial insurance plans. Medicare, which covers the majority of cancer patients, has historically been prohibited from negotiating prices, though the Inflation Reduction Act is beginning to change that for select drugs.
Medicare Part D alone spent over $640 million on Tagrisso in 2019, and that figure has almost certainly grown as the drug’s approved uses expanded. Tagrisso has consistently ranked among the top-selling oncology drugs globally, generating billions in annual revenue for AstraZeneca. The company’s pricing reflects what the market will bear in a system where patients with a life-threatening illness have limited alternatives and insurers absorb much of the cost.
AstraZeneca also invests in clinical trials to expand Tagrisso into new treatment settings, including earlier-stage cancers and combination regimens. These trials are expensive, and pharmaceutical companies fold the cost of ongoing research into their pricing models. Whether that justifies the specific price point is a matter of debate, but it’s part of how the company frames the investment.
Manufacturing Isn’t the Main Cost Driver
Some expensive drugs carry high prices partly because they’re difficult or costly to manufacture. That’s not really the case with Tagrisso. The manufacturing route involves seven chemical steps with a longest sequence of six steps, achieving a yield of about 56 percent. Process development has streamlined production by removing expensive chromatography steps, switching to more practical solvents, and eliminating the need for specialized microwave heating. A continuous flow process for the final two steps achieves yields of 89 percent.
This is a small-molecule pill, not a biologic that requires living cells and cold-chain distribution. The raw manufacturing cost per tablet is a tiny fraction of the retail price. The expense is driven almost entirely by market exclusivity and pricing strategy, not by what it costs to make the drug.
Options for Reducing Your Out-of-Pocket Cost
If you have commercial insurance (not Medicare, Medicaid, or other government coverage), AstraZeneca offers a co-pay savings program with no income requirements. Most eligible patients pay $0 per supply, with the program covering remaining out-of-pocket costs up to an annual maximum.
For uninsured patients or those without prescription drug coverage, the AZ&Me Prescription Savings Program provides the drug at no cost to qualifying applicants. You need to be a U.S. resident, not currently covered by private insurance or a government program (with some Medicare exceptions), and your annual income must fall below a certain level. Medicare beneficiaries enrolled in the Low Income Subsidy for Part D are not eligible.
These programs can dramatically reduce what you actually pay, but they don’t change the underlying price. The full cost still flows to insurers and government programs, which is ultimately reflected in premiums and taxpayer spending. For individual patients, though, assistance programs are often the difference between affording treatment and not.